Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein with
enzymatic carboxypeptidase activity. Expression is seen at low levels in the brain, kidneys …

The introduction of 18F-labeled prostate-specific membrane antigen (PSMA)–targeted
PET/CT tracers, first 18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl) …

Imaging of the prostate-specific membrane antigen (PSMA) has become an important tool
for managing patients with recurrent prostate cancer, and one of the most frequently …

Purpose The prostate-specific membrane antigen (PSMA) targeted positron-emitting-
tomography (PET) tracer 68 Ga-PSMA-11 shows great promise in the detection of prostate …

Biochemical recurrence (BCR) is a concern for prostate cancer patients after local treatment.
68Ga-labeled prostate-specific membrane antigen (PSMA) ligands have significantly …

Molecular imaging with PET using an increasing list of biologically relevant radiotracers is
paving the way for precision and personalized medicine in prostate cancer (1). Prostate …

Local recurrence of prostate cancer after primary local therapy presents challenges for
urologists and imaging procedures, especially in patients with low prostatespecific antigen …

18F-prostate-specific membrane antigen (PSMA)-1007 is excreted mainly through the liver.
We benchmarked the performance of 18F-PSMA-1007 against 3 renally excreted PSMA …

PET imaging with the prostate-specific membrane antigen (PSMA)–targeted radioligand
68Ga-PSMA-11 is regarded as a significant step forward in the diagnosis of prostate cancer …

Purpose The introduction of ligands targeting prostate-specific membrane antigen (PSMA),
especially 68 Ga-PSMA-11, has changed the management of patients with prostate cancer …